Pieris are easy-to-grow and cold-hardy evergreen shrubs with dark fingered foliage that is attractive all year round. This plant (also known as the andromeda bush or the lily-of-the-valley bush) ...

The signing of a lucrative collaboration deal causes the share price to jump. This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone ...

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid truly shocking capital losses. We wouldn't blame Pieris Pharmaceuticals, Inc.

Key Points Pruning in February can stress dormant shrubs or removing potential blooms for certain species.Don't prune gardenias, certain types of hydrangeas, loropetalum, evergreens, or pieris.As an ...

My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

Pieris' PIRS shares were up almost 8% after it announced that it will receive an undisclosed milestone payment from partner Boston Pharmaceuticals related to its pipeline candidate, BOS-342 (formerly ...

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ bought into ...

Pieris Pharmaceuticals is trimming the fat, putting its lead immuno-oncology asset on the chopping block to make more room for its AstraZeneca partnership. With the readout for the ...

Pieris received a grant of $17 million from the Bavarian Ministry of Economic Affairs for a drug to treat lung scarring in COVID sufferers. Shares of Pieris Pharmaceuticals (PIRS) jumped on Friday ...

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology ...